Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTFNGC9)

• DTT Name: Serum albumin (ALB)
• Synonyms: Serum albumin
• Gene Name: ALB
• DTT Type: Successful target; [1]
• Related Disease:
  Aneurysm/dissection [ICD-11: BD50]
  Bowel habit change [ICD-11: ME05]
  Cholelithiasis [ICD-11: DC11]
  Inborn energy metabolism error [ICD-11: 5C53]
  Irritable bowel syndrome [ICD-11: DD91]
  Preprocedural examination [ICD-11: QA0B]
  Rheumatoid arthritis [ICD-11: FA20]
  Schizophrenia [ICD-11: 6A20]
  Unspecific body region injury [ICD-11: ND56]
• UniProt ID: ALBU_HUMAN
• TTD ID: T63068
• Sequence:
  MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
  EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
  ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
  FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
  ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
  ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
  RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
  QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
  LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
  SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
  AASQAALGL
• Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
• Reactome Pathway:
  Recycling of bile acids and salts (R-HSA-159418)
  HDL-mediated lipid transport (R-HSA-194223)
  Scavenging of heme from plasma (R-HSA-2168880)
  Platelet degranulation (R-HSA-114608)

Molecular Interaction Atlas (MIA) of This DTT

9 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Albumin Human	DM5JTPU	Hypoalbuminemia	5C53.2	Approved	[2]
Bismuth	DMTKU46	Diarrhea	ME05.1	Approved	[3]
EVANS BLUE	DM5GT1M	Abdominal aortic aneurysm	BD50.4	Approved	[4]
Gadobenate dimeglumine	DM4VAOG	Schizophrenia	6A20	Approved	[1]
Gadofosveset	DM5V9U1	Imaging	QA0B	Approved	[5]
Iodipamide	DMXIQYS	Gallbladder disease	DC11.3	Approved	[6]
Oxyphenbutazone	DMPZS7U	Arthritis	FA20	Approved	[7]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[8]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[9]

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Activated recombinant FVII-albumin fusion protein	DMKY9GI	Hemophilia	3B10.0	Phase 2/3	[10]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[11]
RU-101	DMXYHC7	Xerophthalmia	5B55.Y	Phase 1/2	[12]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Rheumatoid arthritis	FA20	Synovial tissue	7.92E-01	-0.07	-0.44
Irritable bowel syndrome	DD91.0	Rectal colon tissue	4.95E-01	-0.02	-0.06

References

• [1] Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
• [4] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [5] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [6] Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
• [7] Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
• [8] Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
• [9] Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
• [10] ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of Ablynx.
• [12] Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol. 2003 October; 87(10): 1279-1283.